

A4  
Encd

21. (New) A pharmaceutical composition having antithrombotic efficacy comprising the monoclonal antibody defined in Claim 15 and a pharmaceutically acceptable carrier.--

**REMARKS**

Claims 15-21 are active in this application.

The specification has been amended to include reference to related applications and to correct minor typographical errors. Newly added Claims 15-21 are supported by the specification at pages 9-53 and by claims 1-14 as originally filed. No new matter was added to the application by virtue of the present amendment. Applicants submit that the application is now ready for examination on the merits.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

James J. Kelly, Ph.D.  
Registration No. 41,504

Tel: 703-413-3000  
Fax: 703-413-2220  
NFO:JK:VKS:ksh  
I:\atty\VKS\212033-PrelAmend.wpd



**22850**

---

**MARKED-UP COPY**

Docket No.: 212033US0 DIV

Serial No.: New Application

Amendment Filed: July 31, 2001

---

**IN THE SPECIFICATION**

Please amend the specification as follows:

Please insert the following paragraph on page 1, after line 2:

--(New).--

Please replace the paragraph bridging pages 6 and 7 with the following paragraph:

--Several antibodies against vWF, which inhibit the activity of vWF in vitro, have been hitherto obtained. However, many of them are inferior in reaction specificity, and almost all of them do not inhibit the botrocetin-dependent reaction, even though they inhibit the ristocetin-dependent reaction. As described above, it is considered that the GPIb-binding site on vWF induced by ristocetin is homologous to that induced by botrocetin. Therefore, the foregoing antibodies possibly recognize the binding site on vWF for ristocetin or botrocetin. Strictly speaking, it is possible to say that they do not inhibit the physiological activity of vWF, and hence they have low reaction specificities. In such circumstances, it has been reported that two antibodies, i.e., NMC-4 produced by Fujimura et al. (J. Nara Med. Assoc., vol. 36, p. 662, 1985) and RFF-VIIIRAG:1 produced by Tuddenham et al., inhibit in vitro the reaction depending on both of ristocetin and botrocetin (Blood, vol. [177] 17, No. 1, p. 113, [1992] 1991).--

Page 23, lines 8-24, please replace the paragraph with the following paragraph:

--Thus hybridomas AJvW-1, AJvW-2, AJvW-3, and AJvW-4 have been obtained as demonstrated in Examples described later on. All of them have been deposited on August 24, 1994 in National Institute of Bioscience and Human Technology of Agency of Industrial Science

and Technology of Ministry of International Trade and Industry (postal code: 305, 1-3 Higashi-[Icchome]1-chome, Tsukuba-shi, Ibaraki-ken, Japan) under deposition numbers of FERM P-14486, FERM P-14487, FERM P-14488, and FERM P-14489 respectively in this order, which have been transferred to international deposition based on the Budapest Treaty on September 29, 1995, and deposited under deposition numbers of FERM BP-5247, FERM BP-5248, FERM BP-5249, and FERM BP-5250 respectively in this order. Among the hybridomas, AJvW-2 and AJvW-4 produce the first monoclonal antibody, and AJvW-1 and AJvW-3 produce the second monoclonal antibody.--

**IN THE CLAIMS**

--Claims 15-21 (New).--



**22850**